195 related articles for article (PubMed ID: 33944612)
1.
Pereira DA; Sandrim VC; Palei AC; Amaral LM; Belo VA; Lacchini R; Cavalli RC; Tanus-Santos JE; Luizon MR
Pharmacogenomics; 2021 Jun; 22(8):451-464. PubMed ID: 33944612
[No Abstract] [Full Text] [Related]
2. Gene-gene interactions in the NAMPT pathway, plasma visfatin/NAMPT levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy.
Luizon MR; Palei ACT; Belo VA; Amaral LM; Lacchini R; Duarte G; Cavalli RC; Sandrim VC; Tanus-Santos JE
Pharmacogenomics J; 2017 Oct; 17(5):427-434. PubMed ID: 27168100
[TBL] [Abstract][Full Text] [Related]
3. Effects of NAMPT polymorphisms and haplotypes on circulating visfatin/NAMPT levels in hypertensive disorders of pregnancy.
Luizon MR; Belo VA; Palei AC; Amaral LM; Lacchini R; Sandrim VC; Duarte G; Cavalli RC; Tanus-Santos JE
Hypertens Res; 2015 May; 38(5):361-6. PubMed ID: 25716650
[TBL] [Abstract][Full Text] [Related]
4. NAMPT levels are inversely related to nitric oxide formation and positively related to soluble fms-like tyrosine kinase-1 levels in preeclampsia.
Pereira DA; Sandrim VC; Palei ACT; Tanus-Santos JE; Belo VA; Cavalli RC; Luizon MR
Pregnancy Hypertens; 2019 Oct; 18():137-140. PubMed ID: 31610400
[TBL] [Abstract][Full Text] [Related]
5. The effects of NAMPT haplotypes and metabolic risk factors on circulating visfatin/NAMPT levels in childhood obesity.
Belo VA; Luizon MR; Lacchini R; Miranda JA; Lanna CM; Souza-Costa DC; Tanus-Santos JE
Int J Obes (Lond); 2015 Jan; 39(1):130-5. PubMed ID: 24100423
[TBL] [Abstract][Full Text] [Related]
6.
Luizon MR; Pinto-Souza CC; Coeli-Lacchini F; Lacchini R; Cavalli RC; Sandrim VC
Pharmacogenomics; 2022 Aug; 23(13):713-722. PubMed ID: 35971863
[No Abstract] [Full Text] [Related]
7. The interplay between extracellular NAMPT and inflammatory cytokines in preeclampsia.
Nunes PR; Pereira DA; Passeti LFP; Coura LLF; Gomes KB; Sandrim VC; Luizon MR
J Reprod Immunol; 2024 Jun; 163():104248. PubMed ID: 38703439
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal Study of Plasma Visfatin/Nicotinamide Phosphoribosyltransferase (NAMPT) Levels in Healthy Pregnant Women.
Nunes PR; Cavalli RC; Belo VA; Sandrim VC; Luizon MR
Reprod Sci; 2023 Oct; 30(10):2893-2895. PubMed ID: 37118060
[TBL] [Abstract][Full Text] [Related]
9. Potential roles of visfatin/NAMPT on endothelial dysfunction in preeclampsia and pathways underlying cardiac and vascular remodeling.
Ceron CS; Pereira DA; Sandrim VC; Luizon MR
J Cell Physiol; 2022 Jan; 237(1):10-12. PubMed ID: 34486731
[No Abstract] [Full Text] [Related]
10. A visfatin gene promoter polymorphism (rs1319501) is associated with susceptibility to nonalcoholic fatty liver disease.
Mahmoudi T; Ghorbani D; Rezamand G; Dehestan N; Jeddi G; Asadi A; Nobakht H; Dabiri R; Farahani H; Tabaeian SP; Zali MR
Per Med; 2023 Mar; 20(2):157-165. PubMed ID: 37199515
[No Abstract] [Full Text] [Related]
11. Association of genetic variability in selected regions in visfatin (NAMPT) gene with anthropometric parameters and dietary composition in obese and non-obese Central-European population.
Stastny J; Bienertova-Vasku J; Tomandl J; Tomandlova M; Zlamal F; Forejt M; Splichal Z; Vasku A
Diabetes Metab Syndr; 2013; 7(3):166-71. PubMed ID: 23953183
[TBL] [Abstract][Full Text] [Related]
12. Effects of arginase genetic polymorphisms on nitric oxide formation in healthy pregnancy and in preeclampsia.
Pinto-Souza CC; Coeli-Lacchini F; Luizon MR; Cavalli RC; Lacchini R; Sandrim VC
Nitric Oxide; 2021 May; 109-110():20-25. PubMed ID: 33676021
[TBL] [Abstract][Full Text] [Related]
13. NAMPT (visfatin) and AKT1 genetic variants associate with myocardial infarction.
Leander K; Gigante B; Silveira A; Vikström M; Hamsten A; Högberg J
Clin Chim Acta; 2012 Apr; 413(7-8):727-32. PubMed ID: 22251423
[TBL] [Abstract][Full Text] [Related]
14. Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity.
Romacho T; Azcutia V; Vázquez-Bella M; Matesanz N; Cercas E; Nevado J; Carraro R; Rodríguez-Mañas L; Sánchez-Ferrer CF; Peiró C
Diabetologia; 2009 Nov; 52(11):2455-2463. PubMed ID: 19727662
[TBL] [Abstract][Full Text] [Related]
15. The relationship between circulating visfatin/nicotinamide phosphoribosyltransferase, obesity, inflammation and lipids profile in elderly population, determined by structural equation modeling.
Owczarek AJ; Olszanecka-Glinianowicz M; Kocełak P; Bożentowicz-Wikarek M; Brzozowska A; Mossakowska M; Puzianowska-Kuźnicka M; Grodzicki T; Więcek A; Chudek J
Scand J Clin Lab Invest; 2016 Dec; 76(8):632-640. PubMed ID: 27712122
[TBL] [Abstract][Full Text] [Related]
16. Effects of eNOS polymorphisms on nitric oxide formation in healthy pregnancy and in pre-eclampsia.
Sandrim VC; Palei AC; Sertorio JT; Cavalli RC; Duarte G; Tanus-Santos JE
Mol Hum Reprod; 2010 Jul; 16(7):506-10. PubMed ID: 20457799
[TBL] [Abstract][Full Text] [Related]
17. Proinflammatory actions of visfatin/nicotinamide phosphoribosyltransferase (Nampt) involve regulation of insulin signaling pathway and Nampt enzymatic activity.
Jacques C; Holzenberger M; Mladenovic Z; Salvat C; Pecchi E; Berenbaum F; Gosset M
J Biol Chem; 2012 Apr; 287(18):15100-8. PubMed ID: 22399297
[TBL] [Abstract][Full Text] [Related]
18. Plasma visfatin/nicotinamide phosphoribosyltransferase levels in hypertensive elderly - results from the PolSenior substudy.
Kocelak P; Olszanecka-Glinianowicz M; Owczarek A; Bożentowicz-Wikarek M; Brzozowska A; Mossakowska M; Zdrojewski T; Grodzicki T; Więcek A; Chudek J
J Am Soc Hypertens; 2015 Jan; 9(1):1-8. PubMed ID: 25537462
[TBL] [Abstract][Full Text] [Related]
19. Visfatin -948G/T and resistin -420C/G polymorphisms in Egyptian type 2 diabetic patients with and without cardiovascular diseases.
Motawi TM; Shaker OG; El-Sawalhi MM; Abdel-Nasser ZM
Genome; 2014 May; 57(5):259-66. PubMed ID: 25120107
[TBL] [Abstract][Full Text] [Related]
20. The relationship of visfatin/pre-B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation, insulin resistance, and plasma lipids.
Chang YC; Chang TJ; Lee WJ; Chuang LM
Metabolism; 2010 Jan; 59(1):93-9. PubMed ID: 19765775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
